ãã€ãªå»è¬åäŒæ¥ã® Ovid Therapeutics Inc. ã¯ãç±³åœã§ç¥çµçŸæ£ã®æ£è
ãšå®¶æã®ããã«å¹æçãªå»è¬åãéçºããŠããŸããå瀟ã¯ãæäººã®ã¢ã³ãžã§ã«ãã³çåçŸ€ã®æ²»çè¬ãšããŠç¬¬ III çžèšåºè©Šéšäžã§ããæ°è¬åè£ OV101 ãéçºããŠãããé幎ããã³è¥å¹Žæäººç·æ§ã®è匱 X çåçŸ€ã®æ²»çè¬ãšããŠç¬¬ II çžèšåºè©Šéšãå®äºããŠããŸãããŸãããµã€ã¯ãªã³äŸåæ§ãããŒãŒæ§ 5 æ¬ æçããã³ãã©ãçåçŸ€ã®æ²»çè¬åè£ OV935 ãéçºããŠããã第 II çžèšåºè©Šéšãå®äºããŠããŸããããã«ãå瀟ã¯ãä¹³å
ãããã/çšçºãŠãããã®æ²»çè¬ OV329ãã¢ã³ãžã§ã«ãã³çåçŸ€ã®æ²»çè¬ãšããŠã®ã·ã§ãŒããã¢ãã³ RNA éºäŒåæ²»çè¬ OV882ãããã·ã³ãã¡ããªãŒã¿ã³ãã¯è³ªé¢é£ç¥çµçŸæ£ã®æ²»çè¬éºäŒå調ç¯è¬ OV815 ã®ç ç©¶ããã°ã©ã ã«åãçµãã§ããŸããOvid Therapeutics Inc. ã¯æŠç°è¬åå·¥æ¥æ ªåŒäŒç€Ÿãšææºå¥çŽãçµãã§ããŸãã H. Lundbeck A/Sãšã®ã©ã€ã»ã³ã¹å¥çŽãã³ãã³ãã¢å€§åŠã¢ãŒãŽã£ã³ã°å»çã»ã³ã¿ãŒãšã®æŠç¥çç ç©¶ååãããã³ãšãŒãããã§ã®ã¢ã³ãžã§ã«ãã³çåçŸ€ã®æ²»çè¬OV101ã®éçºãšåååã«é¢ããAngelini Pharmaãšã®ã©ã€ã»ã³ã¹å¥çŽãå瀟ã¯2014幎ã«èšç«ããããã¥ãŒãšãŒã¯å·ãã¥ãŒãšãŒã¯ã«æ¬ç€Ÿã眮ããŠããŸãã